The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs

Jan Bures, Jaroslav Kvetina, Vera Radochova, Ilja Tacheci, Eva Peterova, David Herman, Rafael Dolezal, Marcela Kopacova, Stanislav Rejchrt, Tomas Douda, Vit Sestak, Ladislav Douda, Jana Zdarova Karasova

1 2nd Department of Internal Medicine—Gastroenterology, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital, Hradec Kralove, Czech Republic, 2 Animal Laboratory, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic, 3 Department of Toxicology and Military Pharmacy, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic, 4 Centre of Biomedical Research, University Hospital, Hradec Kralove, Czech Republic, 5 Institute of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital, Hradec Kralove, Czech Republic

These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* bures@lfhk.cuni.cz

Abstract

Background

Memantine, currently available for the treatment of Alzheimer’s disease, is an uncompetitive antagonist of the N-methyl-D-aspartate type of glutamate receptors. Under normal physiologic conditions, these unstimulated receptor ion channels are blocked by magnesium ions, which are displaced after agonist-induced depolarization. In humans, memantine administration is associated with different gastrointestinal dysmotility side effects (vomiting, diarrhoea, constipation, motor-mediated abdominal pain), thus limiting its clinical use. Mechanism of these motility disorders has not been clarified yet. Pigs can be used in various preclinical experiments due to their relatively very similar gastrointestinal functions compared to humans. The aim of this study was to evaluate the impact of a single and repeated doses of memantine on porcine gastric myoelectric activity evaluated by means of electrogastrogaphy (EGG).

Methods

Six adult female experimental pigs (Sus scrofa f. domestica, mean weight 41.7±5.0 kg) entered the study for two times. The first EGG was recorded after a single intragastric dose of memantine (20 mg). In the second part, EGG was accomplished after 7-day intragastric administration (20 mg per day). All EGG recordings were performed under general anaesthesia. Basal (15 minutes) and study recordings (120 minutes) were accomplished using an EGG stand (MMS, Enschede, the Netherlands). Running spectral analysis based on Fourier transform was used. Results were expressed as dominant frequency of gastric slow waves (DF) and power analysis (areas of amplitudes).
**Results**

Single dose of memantine significantly increased DF, from basic values (1.65±1.05 cycles per min.) to 2.86 cpm after 30 min. (p = 0.008), lasting till 75 min. (p = 0.014). Basal power (median 452; inter-quartile range 280–1312 μV²) raised after 15 min. (median 827; IQR 224–2769; p = 0.386; NS), lasting next 30 min. Repetitively administrated memantine caused important gastric arrhythmia. Basal DF after single and repeated administration was not different, however, a DF increase in the second part was more prominent (up to 3.18 ±2.16 after 15 and 30 min., p<0.001). In comparison with a single dose, basal power was significantly higher after repetitively administrated memantine (median 3940; IQR 695–15023 μV²; p<0.001). Next dose of 20 mg memantine in the second part induced a prominent drop of power after 15 min. (median 541; IQR 328–2280 μV²; p<0.001), lasting till 120 min. (p<0.001).

**Conclusions**

Both single and repeated doses of memantine increased DF. Severe gastric arrhythmia and long-lasting low power after repeated administration might explain possible gastric dysmotility side effects in the chronic use of memantine.

**Introduction**

Memantine, an uncompetitive antagonist of the N-methyl-D-aspartate type glutamate receptors (briefly NMDA receptors), is used to treat Alzheimer’s disease (AD) in humans. Under physiologic conditions, this receptor is blocked by magnesium ion, which is displaced upon agonist-induced depolarization. In humans, memantine therapy is associated with gastrointestinal dysmotility (vomiting, diarrhoea, constipation, motor-mediated abdominal pain), thus limiting its clinical use [1–3]. The exact mechanism of these side effects has not been clarified.

Pigs can be used in various preclinical experiments—as omnivores—due to their human-like gastrointestinal physiology [4–8]. Results of experimental studies help to understand mechanisms of drug side effects and this knowledge can be employed into clinical practice. Therefore, the aim of this study was to evaluate the impact of a single and repeated doses of memantine on porcine gastric myoelectric activity by means of electrogastrography (EGG), a non-invasive method for the evaluation of myoelectric activity of the stomach [9–11].

**Material and methods**

**Animals**

Six adult female experimental pigs (*Sus scrofa f. domestica*, hybrids of Czech White and Landrace breeds; 4-months old, mean weight 41.7±5.0 kg) entered the study twice.

All animals were fed with standard assorted A1 food (Ryhos, Novy Rychnov, Czech Republic) of equal amounts twice a day and had free access to drinking water. The acclimatization period was two weeks before the experiment.

**Design of the study**

All EGG recordings were performed under general anaesthesia in the morning after 24 hours of fasting. Intramuscular injections of ketamine (20 mg per kg; Narkamon, Spořa, Praha, Czech Republic) and azaperone (2.2 mg per kg; Stresnil, Janssen Animal Health, Saunderton,
UK) were used as an introduction to anaesthesia in all animals. Intravenous infusion of propofol (AstraZeneca AB, Stockholm, Sweden) was used for subsequent maintenance of general anaesthesia. Two vital signs were monitored, heart rate and pulse oximetry were used to secure the experiments and to assess possible myocardial effect of memantine. Memantine was administered intragastrically by means of a flexible video-gastroscope (GIF-Q130, Olympus Optical Co, Tokyo, Japan), dedicated for animal use only. All endoscopies were video-recorded.

Absorption and distribution of memantine

Concentrations of memantine measured in pig plasma collected after a single intragastric dose (20 mg; day 1), after a 7-day intragastric administration (20 mg per day; 20 mg; day 8) and after 7-day intragastric administration (20 mg per day) with a 40 mg intragastric extra dose three hours later on the last day (60 mg; day 8). Control and additional blood samples were drawn into heparinized tubes from the venous catheter at various time intervals up to 3 hours following the memantine intragastric administration. The blood samples (1 mL whole blood/time interval) at regular time intervals: 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 min was drawn. Plasma was prepared by centrifugation (1050 g, 10 min, 25˚C, Centrifuge Z 206 A, Hermle, Germany) immediately after sampling and frozen at -80˚C prior to analysis.

During the organ distribution study, the concentrations of memantine in pig plasma and selected organs or body fluids were collected after a 7-day intragastric administration of 20 mg per day, with a 40 mg extra dose on day 8 (administered 150 minutes after the last 20-mg dose). Ninety minutes after this extra dose of 40 mg of memantine, the pigs were sacrificed by means of pharmacological euthanasia (T61, Intervet International BV, Boxmeer, the Netherlands; dose of 2 mL/kg), exsanguinated and immediate autopsy was performed. The blood and selected organs (heart, lung, muscle, fat, spleen, liver, kidney, gastric and intestinal wall, selected parts of brain) were taken. For the elimination study the urine directly from bladder and bile from gallbladder were taken.

HPLC analysis of memantine

Reagents and chemicals. Methanol, formic acid (both for mass spectrometry gradient grade), sodium hydroxide, diethyl ether, chloroform (all HPLC grade), memantine and amantadine (internal standard, IS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ultrapure water was produced by Aqua Osmotic 06 (Aqua Osmotic, Tisnov, Czech Republic). Supelco Supelclean LC-WCX (1 mL, 100 mg) SPE cartridges were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Standard solution, calibration standard. Stock solutions of memantine and amantadine (internal standard; IS, 100 μg.mL-1) were prepared in ultrapure water. Standard working solutions for calibration curves were prepared by diluting the stock solutions with water. Calibration standards were prepared by spiking blank matrix (990 μL) with 10 μL of a standard working solution to give concentrations in matrix from 2 to 10000 ng.mL-1. The IS working solution (1 μg.mL-1) was obtained by dilution of stock solution.

Sample preparation. Plasma, urine or bile (1 mL) was spiked with 20 μL of IS working solution. After spiking the mixture was loaded onto a SPE Supelclean LC-WCX cartridge, preconditioned with methanol (1 mL) and water (1 mL). The cartridge was washed with water (1 mL) and eluted with 5% formic acid in methanol (1 mL). Eluate was evaporated by using rotational vacuum concentrators UNIVAPO 100 ECH (UniEquip GmbH., Germany). The residue was reconstituted with 500 μL water. Finally, 25 μL were injected to LC–MS system.
Tissues samples were mixed with water in a ratio of 1:4 and subsequently homogenized at 15000 rpm for 1 min by Turax T25 (IKA Labortechnik, Staufen, Germany) and for 30 sec by ultrasonic homogenizer UP 50H (Hielscher Ultrasonics, Teltow, Germany), the mixture was centrifuged (10 min, 4˚C, 5000 × g). Extraction of memantine and amantadine from tissue samples was a modification of the method published previously [12]. Supernatant (500 μL) was mixed with 150 μL of 0.05 M NaOH and 20 μL of IS working solution. The mixture was then shaken with 3 mL of diethyl ether-chloroform (7:3, v/v) for 5 min at 1500 RPM. After centrifugation (5 min, 16000 × g), the upper organic layer was transferred to a clean tube and evaporated by Vacuum Concentrator at 45˚C (UNIVAPO 100 ECH, UniEquip, Planegg, Germany). The residue was reconstituted with 500 μL water. Finally, 25 μL were injected to LC–MS system.

**LC-MS/MS equipment and parameters.** LC-MS analysis was carried out using a Finnigan Surveyor plus system (Thermo Scientific, San Jose, CA, USA), consisting of a quaternary MS pump with integrated degasser and an auto sampler with integrated column oven. The chromatographic separation was performed on a Kinetex C18 column (5 μm, 50 mm × 4.6 mm I.D.) preceded by a C18 security guard cartridge (4.0 mm × 3.0 mm I.D.) both by Phenomenex (Torrance, CA, USA). Separation was attained using an isocratic elution with a flow rate of 0.5 mL.min⁻¹. The column and tray temperature were set at 25 and 10˚C, respectively. The mobile phase consisted of 0.5% formic acid in water and methanol (45:55 v/v). The run time of analysis was 3 min.

Mass spectrometry was performed on an LTQ XL linear ion trap instrument (Thermo Scientific, San Jose, CA, USA), coupled with heated electrospray ionization (HESI-II) probe operated in positive mode. After optimization, the parameters in the source were set as follows: source voltage 4.5 kV, source heater temperature 250˚C, sheath gas flow 30 arb and auxiliary gas flow 10 arb. The mass spectrometer was operated in selected reaction monitoring (SRM) mode. The fragment ions m/z 180 → 163 and m/z 152 → 135 were used for quantification of memantine and amantadine, respectively. Thermo Fisher Xcalibur software was used for the analysis.

**Electrogastrography**

The first EGG was recorded after a single intragastric dose of memantine (20 mg), followed by a 7-day wash-out period. The second EGG was taken after 7-day intragastric administration (20 mg per day). All EGG recordings were performed under general anaesthesia, using our own method [4,13–16]. Briefly, all animals were lying in a right lateral position. The epigastric area was shaved first and the skin was gently sandpapered afterwards. Six active self-adhesive electrodes were placed on the upper part of the abdomen, the 7th electrode (basal) was placed left of the middle sternum. A special abdominal belt (respiratory sensor) was used to identify possible artefacts due to breathing and body movements. Basal (15 minutes) and study recordings (120 minutes) were accomplished using an EGG stand (MMS, Enschede, the Netherlands). MMS software (version 8.19) was used to assess EGG recordings. Running spectral analysis (based on Fourier transform) was used for the elemental evaluation of the EGG. The results were expressed as dominant frequency of slow waves at all intervals of EGG recordings. EGG power analysis (areas of amplitudes) was accomplished afterwards in all animals.

**Statistical analysis**

Data were statistically treated by means of descriptive statistics, non-paired t-test, Mann-Whitney rank sum test and Pearson product moment correlation using the SigmaStat software (Version 3.1, Jandel Corp, Erkrath, Germany).
Ethics

The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies [17]. The Project was approved by the Institutional Review Board of the Animal Care Committee of the University of Defence (No. 19/19), Faculty of Military Health Services, Hradec Kralove, Czech Republic. Animals were held and treated in accordance with the European Convention for the Protection of Vertebrate Animals [18].

![Graph showing levels of memantine measured in pig plasma](https://doi.org/10.1371/journal.pone.0227781.g001)

Fig 1. Levels of memantine measured in pig plasma collected after a single intragastric dose, after a 7-day intragastric administration and after 7-day intragastric administration with a 40 mg intragastric extra dose.

https://doi.org/10.1371/journal.pone.0227781.g001
Results

Absorption and distribution of memantine

Fig 1 shows the time-concentration curves of memantine in plasma after intragastric administration in pigs (n = 6).

There is little difference in concentrations after single and repeated administration after 150 minutes, but the eventual addition of 40 mg of intragastric memantine is marked by a steep rise in plasmatic concentration. The peak concentration after the last administration comes at 75 minutes and appears to stay stable until the end of the experiment.

Table 1 gives data on organ distribution after a 7-day intragastric administration (20 mg per day), with a 40 mg extra dose last day (three hours after the last 20 mg dose). To compare the bio-distributive relationships of memantine in particular tissues we also present organ/plasma ratios. The substantial difference in gastrointestinal tract to blood is probably due to the short period between last administration and the autopsy.

Electrogastrography

A single dose of memantine nearly doubled the dominant frequency (DF), from initial values (1.65±1.05 cycles per min.) to 2.86 cpm after 30 min. (p = 0.008). This effect lasted up to 75 min. (p = 0.014). Repeated administration of memantine caused marked gastric arrhythmia (Fig 2).

Table 1. Concentrations of memantine in pig plasma and selected organs/body fluids collected after a 7-day intragastric administration of 20 mg per day, with a 40 mg extra dose last day (administered 150 minutes after the last 20-mg dose on day 8).

| Tissue              | Mean ± SEM (ng/mL or g) | Tissue or body fluid/ plasma ratio |
|---------------------|-------------------------|-----------------------------------|
| plasma              | 5.08 ± 0.99             | 1.00                              |
| stomach             | 433.90 ± 160.61         | 85.41                             |
| proximal jejunum    | 3066.44 ± 715.63        | 603.63                            |
| med jejunum         | 2784.51 ± 925.09        | 548.13                            |
| distal jejunum      | 731.32 ± 445.02         | 143.96                            |
| muscle              | 33.99 ± 17.28           | 6.69                              |
| fat                 | 23.37 ± 3.62            | 4.60                              |
| spleen              | 68.51 ± 13.96           | 13.49                             |
| liver               | 535.88 ± 138.03         | 105.49                            |
| kidney              | 41.96 ± 8.32            | 8.26                              |
| heart               | 28.93 ± 11.33           | 5.69                              |
| lung                | 444.73 ± 116.04         | 87.55                             |
| medulla             | 49.57 ± 19.53           | 9.76                              |
| medulla oblongata   | 22.90 ± 8.94            | 4.51                              |
| hemisphere          | 15.76 ± 6.56            | 3.10                              |
| front lobe          | 26.53 ± 7.62            | 5.22                              |
| cerebellum          | 14.76 ± 5.34            | 2.91                              |
| pituitary gland     | 100.40 ± 34.70          | 19.76                             |
| hippocampus         | 52.75 ± 16.74           | 10.38                             |
| diencephalon        | 26.30 ± 7.71            | 5.18                              |
| urine               | 75.46 ± 22.75           | 14.85                             |
| bile                | 40.27 ± 12.01           | 7.93                              |

https://doi.org/10.1371/journal.pone.0227781.t001
Basal DF after single and repeated administration were comparable, however, the DF increase was more prominent in the latter (up to 3.18±2.16 after 15 and 30 min., p<0.001) (Figs 3 and 4).

Basal power (median 452; IQR 280–1312 μV^2) also rose 15 minutes after a single dose (median 827; IQR 224–2769; p = 0.386; NS), remaining increased up to 30 min (Figs 4 and 5). In comparison, basal power was significantly higher after repetitively administered memantine (median 3940; IQR 695–15023 μV^2; p<0.001). The additional dose of 20 mg memantine induced a prominent drop of power after 15 min (median 541; IQR 328–2280 μV^2; p<0.001), lasting up to 120 min. (p<0.001) (Figs 5 and 6).

**Discussion**

Our current study brings an important new insight into understanding the effect of memantine on gastric myoelectric activity. We used surface electrogastrography (EGG), a non-invasive method for assessment of gastric myoelectrical activity [9–11], which gives comparable results in pigs and in healthy humans, both in dominant frequency and EGG power (areas of amplitudes) [13–16]. In our current study, single dose of memantine significantly increased DF, while repetitively administrated memantine caused important gastric arrhythmia. Basal DF after single and repeated administration was not different, however, a DF increase in the second part was more prominent. In comparison with a single dose, basal power was significantly higher after repetitively administrated memantine. Next dose of 20 mg memantine in the second part induced a prominent drop of the EGG power. In our previous studies, porcine dominant frequency on EGG was fully comparable with the values of healthy humans [13–16]. We tested different types of anaesthesia previously and found no significant difference [15]. As a new finding, we currently found bradygastria within the baseline EGG recording of fasting animals. It might be, at least partially, explained by an effect of propofol. We have been using propofol recently as it shortens the general anaesthesia and makes the rapid recovery possible.
Propofol can influence both gastric and intestinal motor function in humans and in an experimental setting [19–22].

We focused on determination of plasmatic concentration-time profile of memantine after single, repeated and additional administration. We found no correlation between EGG parameters and serum concentration or organ distribution of memantine. The high concentration in proximal jejunum is in good agreement with fast absorption after i.g. administration; the peak concentrations were reached within 75 to 150 min after administration in all cases. We observed little difference in the peak concentrations throughout the experiment, safe for the additional administration of 40 mg of memantine at the end of the experiment, where the concentrations more than doubled. This observation, nonetheless, corroborates the previously published data on linearity of memantine pharmacokinetics (in this case the standard dose of 20 mg with subsequent dose of 40 mg of memantine) [23]. The memantine levels were relatively stable after completion of absorption, which is well in line with the long elimination half-life described earlier [24]. This assumption is also supported by the strong distribution of memantine into peripheral organs and central nervous system, as seen in this work and in literature [25–27].

The ability to cross the blood brain barrier and to reach the site(s) of action are the mandatory prerequisites for successful anti-AD treatment [28,29]. Memantine is a cationic
amphiphilic substance and as such should pass through biological membranes in its unionized form by passive diffusion [30]. Studies proving the blood-brain barrier permeation, active/facilitated transport or accumulation of memantine within the target brain structures are still rare. According to our results, the brain concentrations of memantine were more than twice as big as in plasma in all cases [25–27]. As we expected, the memantine concentration in various brain regions were comparable with peripheral fat concentration, indicating the vast distribution of the drug within tissues. These lipophilic depots are probably responsible for the long elimination half-life of memantine [26,27]. Difference in concentration of memantine in the pituitary gland compared to other brain regia suggests the involvement of blood-brain barrier. The direct connection of the pituitary gland and hippocampus might explain the relatively high concentration in the latter. This may also explain the pharmacodynamic effect of memantine via local MNDA receptors.

Memantine is primarily excreted unmetabolized via kidney, low concentration in the kidney tissue (compared to relatively higher concentration in urine) indicates active tubular secretion and low tubular reabsorption [31]. The small extent to which it is metabolized by CYP450 2B6 corresponds with the observed low concentration in liver tissue [32].

Memantine is believed to block the current flow through channels of NMDA glutamate receptor [33,34]. NMDA receptors are involved in the regulation of many gastric functions: 1)
hydrochloric acid production [35], 2) glutamatergic, cholinergic and non-cholinergic pathways [36–38], 3) ghrelin mediated processes [12], 4) visceral pain [39], 5) chronic Helicobacter pylori infection [40], 6) gastric accommodation and emptying [41] and other. NMDA receptors also participate in the brain-gut axis regulation [42] and function of the lower oesophageal sphincter [43]. Thus, the complex action of this drug can 1) explain the gastrointestinal dysmotility side effects of memantine and 2) be possibly of use in treatment of dyspepsia and nausea [39,44]. Recently, data on possible memantine prophylaxis against soman poisoning were published. It appears memantine counteracts the poisoning symptoms via a combination of acetylcholinesterase-protection and NMDA receptor-blockade [45,46].

We used a single low dose of ketamine–another NMDA blocker–as introduction to anaesthesia, so possible gastric myoelectric effect of ketamine, might have influenced the basal EGG recording. The study of memantine effect itself remained however unaffected, because the mechanism of action of the two NMDA-receptor modulators is quite distinct, and because a blank reading was performed [47].

Surprisingly, we found no connection between EGG parameters and serum concentration or organ distribution of memantine. We hypothesize that memantine affects the myoelectric activity of the stomach directly by topical effect and by systemic plasmatic circulation.
Conclusions

Both single and repeated doses of memantine increased DF. Severe gastric arrhythmia and long-lasting low power after repeated administration might explain possible gastric dysmotility side effects in the chronic use of memantine.

Acknowledgments

Preliminary results of the study were presented in part, as a poster, at the 26th United European Gastroenterology Week, Vienna, October 20–24, 2018 (abstract published in UEG J 2018; 6, Suppl 1: A296).

Author Contributions

Conceptualization: Jan Bures, Jaroslav Kvetina, Vera Radochova, Ilja Tacheci, Eva Peterova, David Herman, Rafael Dolezal, Marcela Kopacova, Stanislav Rejchrt, Tomas Douda, Vit Sestak, Ladislav Douda, Jana Zdarova Karasova.

Data curation: Jan Bures, Ilja Tacheci, Eva Peterova, Ladislav Douda, Jana Zdarova Karasova.

Formal analysis: Jan Bures, Jaroslav Kvetina, Ilja Tacheci, Eva Peterova, Jana Zdarova Karasova.

Funding acquisition: Jan Bures, Jana Zdarova Karasova.

Fig 6. Electrogastrography. Power analysis (areas of amplitudes; mean ± S.D.) before (BASAL) and after the administration of 20 mg memantine on day 8 (eight 15-minute intervals).

https://doi.org/10.1371/journal.pone.0227781.g006
Investigation: Jan Bures, Jaroslav Kvetina, Vera Radochova, Ilja Tacheci, Eva Peterova, David Herman, Rafael Dolezal, Marcela Kopacova, Stanislav Rejchrt, Vit Sestak, Ladislav Douda, Jana Zdarova Karasova.

Methodology: Jan Bures, Jaroslav Kvetina, Vera Radochova, Ilja Tacheci, Eva Peterova, Rafael Dolezal, Marcela Kopacova, Stanislav Rejchrt, Tomas Douda, Vit Sestak, Jana Zdarova Karasova.

Project administration: Jan Bures, Vera Radochova, Ilja Tacheci, Jana Zdarova Karasova.

Resources: Jan Bures, Jana Zdarova Karasova.

Supervision: Jan Bures, Jaroslav Kvetina, Vera Radochova, Ilja Tacheci, Marcela Kopacova, Jana Zdarova Karasova.

Validation: Jan Bures, Jaroslav Kvetina, David Herman, Rafael Dolezal, Jana Zdarova Karasova.

Visualization: Jan Bures, Jana Zdarova Karasova.

Writing – original draft: Jan Bures, Jana Zdarova Karasova.

Writing – review & editing: Jan Bures, Jaroslav Kvetina, Vera Radochova, Ilja Tacheci, Eva Peterova, David Herman, Rafael Dolezal, Marcela Kopacova, Stanislav Rejchrt, Tomas Douda, Vit Sestak, Ladislav Douda, Jana Zdarova Karasova.

References
1. Wang X, Blanchard J, Grundke-Iqbal I, Iqbal K. Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. PLoS One. 2015; 10(12): e0145441. https://doi.org/10.1371/journal.pone.0145441 PMID: 26697860
2. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015; 10(4): e0123289. https://doi.org/10.1371/journal.pone.0123289 PMID: 25860130
3. Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One. 2017; 12(8): e0183586. https://doi.org/10.1371/journal.pone.0183586 PMID: 28827830
4. Bures J, Kvetina J, Pavlik M, Kunes M, Kopacova M, Rejchrt S et al. Impact of paraoxon followed by acetylcholinesterase reactivator Hi-6 on gastric myoelectric activity in experimental pigs. Neuro Endocrinol Lett. 2013; 34, Suppl 2: 79–83.
5. Bures J, Pejchal J, Kvetina J, Tichy A, Rejchrt S, Kunes M et al. Morphometric analysis of the porcine gastrointestinal tract in a 10-day high-dose indomethacin administration with or without probiotic bacteria Escherichia coli Nissle 1917. Hum Exp Toxicol. 2011; 30: 1955–1962. https://doi.org/10.1177/0960377111403174 PMID: 21441285
6. Bures J, Smaja D, Kvetina J, Förstl M, Smarda J, Kohoutova D et al. Bacteriocolony in experimental pigs treated with indomethacin and Escherichia coli Nissle. World J Gastroenterol. 2011; 30: 1955–1962.
7. Kararli TT. Comparison of the gastrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos. 1995; 16: 351–380. https://doi.org/10.1002/bdd.2510160502 PMID: 8527686
8. Suenderhauf C, Parrott N. A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation. Pharm Res. 1995; 30: 1–15.
9. Chen JZ, McCallum RW (Eds). Electrogastrography. Principles and Applications. New York: Raven Press, 1994.
10. Parkman HP, Hasler WL, Barnett JL, Eaker EY, American Motility Society Clinical GI Motility Testing Task Force. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterol Motil. 2003; 15: 89–102. https://doi.org/10.1046/j.1365-2982.2003.00396.x PMID: 12680908
11. Koch KL, Stern RM. Handbook of Electrogastrography. Oxford: Oxford University Press, 2004.
12. Gong Y, Liu Y, Liu F, Wang S, Jin H, Guo F et al. Ghrelin fibers from lateral hypothalamus project to nucleus tractus solitaries and are involved in gastric motility regulation in cisplatin-treated rats. Brain Res. 2017; 1659: 29–40. https://doi.org/10.1016/j.brainres.2017.01.004 PMID: 28093190
13. Edakkamambh Varayil J, Ali SM, Tacheci I, Kvetina J, Kopacova M, Kunes M et al. Electrogastrography in experimental pigs. Methodical design and initial experience. Folia Gastroenterol Hepatol. 2009; 7: 98–104. Available from www.pro-folia.org.
14. Tacheci I, Kvetina J, Kunes M, Edakkamambh Varayil J, Ali SM, Pavlik M et al. Electrogastrography in experimental pigs: the influence of gastrointestinal injury induced by dextran sodium sulphate on porcine gastric erythromycin-stimulated myoelectric activity. Neuroendocrinol Lett. 2011; 32, Suppl 1: 131–136.
15. Tacheci I, Kvetina J, Kunes M, Pavlik M, Kopacova M, Cerny V et al. The effect of general anaesthesia on gastric myoelectric activity in experimental pigs. BMC Gastroenterol. 2013; 13: 48. https://doi.org/10.1186/1471-230X-13-48 PMID: 23946859
16. Kvetina J, Tacheci I, Pavlik M, Edakkamambh Varayil J, Ali SM, Tachec i I, Kvetina J, Kopacova M, Cerny V et al. Electroga strography in pre-
17. Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. Basic Clin Pharmacol Toxicol. 2018; 123: 233–235. https://doi.org/10.1111/bcpt.13059 PMID: 29931751
18. Explanatory Report on the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (ETS 123). Strasbourg: Council of Europe, 2009.
19. Lee TL, Ang SB, Dambsya YM, Adaikan GP, Lau LC. The effect of propofol on human gastric and colonic muscle contractions. Anesth Analg. 1999; 89: 1246–1249. PMID: 10553844
20. Schnoor J, Bartz S, Klosterhalber B, Kuepper T, Bode B, Hofeditz A, Rossaint R, Unger JK. A long-term porcine model for measurement of gastrointestinal motility. Lab Anim. 2003; 37: 145–154. https://doi.org/10.1258/0026770360563796 PMID: 12689426
21. Schnoor J, Unger JK, Kuepper T, Bode B, Hofeditz A, Silny J, Rossaint R. Effects of propofol and fentanyl on duodenal motility activity in pigs. Can Vet J. 2005; 46: 995–1001. PMID: 16363326
22. Memi D, Dökmeci D, Karamanlioglu B, Tunar A, Türe M. A comparison of the effect on gastric emptying of propofol or dexametomidine in critically ill patients: preliminary study. Eur J Anaesthesiol. 2006; 23: 700–704. https://doi.org/10.1017/S0265022047000172 PMID: 16805936
23. Liu MY, Meng S-N, Wu H-Z, Wang S, Wei M-J. Pharmacokinetics of single-dose and multiple-dose memantine in healthy volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clin Ther. 2008; 30: 641–653. https://doi.org/10.1016/j.clinthera.2008.04.005 PMID: 18498913
24. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018; 51: 9–62. https://doi.org/10.1055/s-0043-116492 PMID: 28910830
25. Ametamey SM, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M et al. PET studies of 18F-memantine. J Cereb Blood Flow Metab. 2002; 22: 227–231. https://doi.org/10.1097/01.mtb.0000015836.09024.c7 PMID: 11823128
26. Victorino DB, Bederman IR, Costa ACS. Pharmacokinetic properties of Memantine after a single intraperitoneal administration and multiple oral doses in euploid mice and in the Ts65Dn mouse model of Down's syndrome. Bas Clin Pharmacol Toxicol. 2017; 121: 382–389.
27. Wesemann W, Schollmeyer JD, Sturm G. Distribution of memantine in brain, liver, and blood of the rat. Arzneimittelforshung 1982; 32: 1243–1245. PMID: 68911224
28. Karasova JZ, Sestak V, Korabecny J, Mezileova E, Palicka V, Kucia K et al. 1-Benzyl-4-methylpiperidinyl moiety in donepezil: The priority ticket across the blood-brain-barrier in rats. J Chrom B. 2018; 1092: 350–358.
29. Karasova JZ, Mzik M, Hroch M, Korabecny J, Nepovimova E, Vorisek V et al. The new acetycholines-}
30. Honegger UE, Quack G, Wiesmann UN. Evidence for lysosomotropic of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharmacol Toxicol. 1993; 73: 202–208. https://doi.org/10.1111/j.1600-0773.1993.tb01564.x PMID: 8295847
31. Pericloo A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharm Ther. 2006; 79: 134–143.

32. Micuda S, Mundlova L, Anzenbacherova E, Anzenbacher P, Chladek J, Fuksa L, Martinkova J. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol. 2004; 60: 583–589. https://doi.org/10.1007/s00228-004-0825-1 PMID: 15378224

33. Johnson JW, Kotermski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006; 6: 61–67. https://doi.org/10.1016/j.coph.2005.09.007 PMID: 16368266

34. Johnson J.W.; Glasgow N.G.; Povysheva N.V. Recent insights into the mode of action of memantine and ketamine. Curr Opin Pharmacol. 2015; 20: 54–63. https://doi.org/10.1016/j.coph.2014.11.006 PMID: 25462293

35. Golovynska I, Beregovaya TM, Falalyeyeva TM, Stepanova LI, Golovynskiy S, Qu J et al. Peripheral N-methyl-D-aspartate receptor localization and role in gastric acid secretion regulation: immunofluorescence and pharmacological studies. Sci Rep. 2018; 8: 7445. https://doi.org/10.1038/s41598-018-25753-6 PMID: 29749407

36. Clyburn C, Travaglì RA, Browning KN. Acute high-fat diet upregulates glutamatergic signaling in the dorsal motor nucleus of the vagus. Am J Physiol Gastrointest Liver Physiol. 2018; 314: G623–G634. https://doi.org/10.1152/ajpgi.00395.2017 PMID: 29368945

37. Jocic M, Schuligoi R, Schönnike E, Pabst MA, Holzer P. Cooperation of NMDA and tachykinin NK(1) and NK(2) receptors in the medullary transmission of vagal afferent input from the acid-threatened rat stomach. Pain. 2001; 89: 147–157. https://doi.org/10.1016/s0304-3959(00)00357-2 PMID: 11166470

38. Kohijitani A, Funahashi M, Miyawaki T, Hanazaki M, Matsuo R, Shimada M. Peripheral N-methyl-D-aspartate receptors modulate nonadrenergic noncholinergic lower esophageal sphincter relaxation in rabbits. Anesth Analg. 2005; 101: 1681–1688. https://doi.org/10.1213/01.ANE.0000184137.37687.B7 PMID: 16301241

39. Kuiken SD, Lei A, Tytgat GN, Holman R, Boeckxstaens GE. Effect of the low-affinity, noncompetitive N-methyl-D-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. Aliment Pharmacol Ther. 2002; 16: 1955–1962. https://doi.org/10.1046/j.1365-2036.2002.01358.x PMID: 12936010

40. Seo JH, Fox JG, Peak RM Jr, Hagen SJ. N-methyl-D-aspartate channels link ammonia and epithelial cell death mechanisms in Helicobacter pylori infection. Gastroenterology 2011; 141: 2064–2075. https://doi.org/10.1053/j.gastro.2011.06.046 PMID: 21925124

41. Cremonini F, Delgado-Aros S, Talley NJ. Functional dyspepsia: drugs for new (and old) therapeutic targets. Best Pract Res Clin Gastroenterol. 2004; 18: 717–733. https://doi.org/10.1016/j.bpg.2004.04.003 PMID: 15324710

42. Landeira-Fernandez J. Participation of NMDA receptors in the lateral hypothalamus in gastric erosion induced by cold-water restraint. Physiol Behav. 2015; 140: 209–214. https://doi.org/10.1016/j.physbeh.2014.12.038 PMID: 25542887

43. Kohijitani A, Funahashi M, Miyawaki T, Hanazaki M, Matsuo R, Shimada M. Peripheral N-methyl-D-aspartate receptors modulate nonadrenergic noncholinergic lower esophageal sphincter relaxation in rabbits. Anesth Analg. 2005; 101: 1681–1688. https://doi.org/10.1213/01.ANE.0000184137.37687.B7 PMID: 16301241

44. Jocic M, Schuligoi R, Schönnike E, Pabst MA, Holzer P. Cooperation of NMDA and tachykinin NK(1) and NK(2) receptors in the medullary transmission of vagal afferent input from the acid-threatened rat stomach. Pain 2001; 89: 147–157. https://doi.org/10.1016/s0304-3959(00)00357-2 PMID: 11166470

45. Stojilkovic MP, Škrbić R, Jokanović M, Bokonjić D, Kilibarda V, Vulović M. Prophylactic potential of memantine against soman poisoning in rats. Toxicology 2019; pii: S0300-483X(19)30061-7. https://doi.org/10.1016/j.tox.2019.01.012 Epub ahead of print. PMID: 30682440

46. Almeida AA, Campos DR, Bernasconi G, Calafatti S, Barros FAP, Eberlin MN et al. Determination of memantine in human plasma by liquid chromatography–electrospray tandem mass spectrometry: Application to a bioequivalence study. J Chromatogr B. 2007; 848: 311–316.

47. Bures J, Kvetina J, Tacheči I, Pavlík M, Kunes M, Rejčrt S et al. The effect of different doses of atropine on gastric myoelectric activity in fasting experimental pigs. J Appl Biomed. 2015; 13: 273–277.